Navigation Links
NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
Date:4/29/2009

1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently evaluating the timing of entering Phase 2 development.

NeurogesX' early stage product pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the size, scope and growth of potential markets for NeurogesX' product candidates; and the expected benefits of NeurogesX' product candidates and its plans with regard to seeking potential development partners for its early stage product pipeline. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; any regulatory approvals which are received may be limited to certain indications; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; physician or patient reluctance to use Qutenza or NGX-1998, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret pr
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
2. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
3. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
4. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
5. NeurogesX Reports Third Quarter 2008 Results
6. NeurogesX to Report Third Quarter 2008 Financial Results
7. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
8. NeurogesX Responds to EMEAs Day 120 Questions
9. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
10. NeurogesX Reports Second Quarter 2008 Results
11. NeurogesX to Report Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... PRC Clinical, a full-service, ... Bay Area, will exhibit and present at the ... on March 25th and 26th in Tel Aviv, Israel. ... Israeli life science companies seeking to conduct U.S. Food ... span all phases of human trials, from Phase I ...
(Date:3/4/2015)... 04, 2015 Follow us on ... of the fastest growing technologies in the life sciences ... visualization is driving growth in nucleic acid detection technologies ... of gene expressions will continue to benefit the qPCR ... fields ranging from pharma, biotech, food & beverage to ...
(Date:3/3/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be ... Miami, FL on March 10, 2015 at ... Chief Financial Officer, will provide a corporate overview. ... Halozyme,s corporate website at www.halozyme.com , and a recording ... To access the live webcast, please log on to Halozyme,s ...
(Date:3/3/2015)... SAN DIEGO , March 3, 2015  Neurocrine ... that Kevin Gorman , President and Chief Executive ... Barclays Global Healthcare Conference in Miami.   ... at 10:15am ET (7:15am PT).  The presentation will be ... at http://www.neurocrine.com .   Listeners are ...
Breaking Biology Technology:PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2
... N.Y., Jan. 28 XTL Biopharmaceuticals Ltd. (Nasdaq: ... January 27, 2009 it received a Staff Determination Letter ... the Company that the staff of Nasdaq,s Listing Qualifications ... Rule 4300, that the Company,s American Depository Shares ("ADRs") ...
... Binding Site Limited,("The Binding Site" or the "Company"), ... publication of the first,international guidelines recommending first-line use ... myeloma, a cancer of cells in the bone,marrow, ... The guidelines were written on behalf ...
... Business Development , ... Olyphant, PA (PRWEB) January 28, 2009 -- ... the hiring of Mr. Terry Ladd as Vice President of Business Development. ... Director, Business Development and Marketing., , , , ,Mr. Ladd will be ...
Cached Biology Technology:International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 2International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 3International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 4International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 5International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 6International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 7Calvert Labs Announces the Hiring of Terry Ladd 2
(Date:2/5/2015)... 2015 Despite a lack of advancements ... as consumer electronics, automotive, storage and telecommunication has ... (SMT) screen printers. Innovations in electronics and conversion ... the adoption curve up. Meanwhile, sale volumes of ... dispensers are indispensable in the production of complex ...
(Date:1/22/2015)... CHICAGO , Jan. 9, 2015 Valid S.A. ("Company") ... the market in general the State of Washington,s ... contract for a new enrollment and central issuance system for ... The project planning and development will start ...
(Date:1/22/2015)... Fla. , Jan. 13, 2015  Today, FreeWavz ... technology, launched its crowdfunding campaign on Fundable, ... the build of production capacity to meet customer ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
... in Munich, Germany and Ann Arbor, Michigan released today ... National Institute on Aging, National Institutes of Health, Baltimore, ... cells. , In their work they first identified and ... methods. Then they employed extensive DNA promoter analysis based ...
... Throughout the world, amateurs, experts and the media agree ... that the bodys own opioids, so called endorphins, are ... never been proved until now. Researchers at the Technische ... demonstrate the existence of an endorphin driven runners high. ...
... ... Entry, WASHINGTON, Feb. ... Department of Homeland Security (DHS) is,expanding the operation of their successful biometrics-at-sea ... securing the more than 95,000 miles of,America,s coastline," said Rear Adm. Wayne ...
Cached Biology News:The myth of runner's high revisited with brain imaging 2The myth of runner's high revisited with brain imaging 3DHS Expands Biometrics-at-Sea Program to the Florida Straits 2
Alkaline Phosphatase Stabilizer Solution, 1 L...
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5...
... Our fastest automated perfusion system. ... in perfusion, physiology, biophysics, electrochemistry, or ... reproducibility with 1.5-4 millisecond accuracy ... Microprocessor-based for accuracy and flexibility ...
Biology Products: